| Identification | Back Directory | [Name]
L-Lysine, N6-[4-(4-iodophenyl)-1-oxobutyl]-, methyl ester | [CAS]
2088426-96-2 | [Synonyms]
L-Lysine, N6-[4-(4-iodophenyl)-1-oxobutyl]-, methyl ester | [Molecular Formula]
C17H25IN2O3 | [MOL File]
2088426-96-2.mol | [Molecular Weight]
432.3 |
| Chemical Properties | Back Directory | [Boiling point ]
539.5±50.0 °C(Predicted) | [density ]
1.411±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
16.26±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC)[1][2]. | [References]
[1] Sun M, et al. Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. Curr Oncol Rep. 2021 Mar 29;23(5):59. DOI:10.1007/s11912-021-01042-w
[2] Zitzmann-Kolbe S, et al., Preclinical evaluation of an actinium-225 labeled PSMA-targeting small molecule (225Ac-PSMA-Trillium (BAY 3563254)) for the treatment of metastatic castration resistant prostate cancer (mCRPC)[J]. Cancer Research, 2024, 84(6_Supplement): 6033-6033. |
|
|